IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMM

IMM - IMMUTEP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.315

20 Feb
2025

-0.015

OPEN

$0.33

-4.55%

HIGH

$0.33

1,807,013

LOW

$0.32

TARGET
$0.70 122.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMM: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 3.6 - 5.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-3.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx13.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-34.8 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-26.21 %
Return on Invested Capital xxxxxxxxxxxxxxx-26.02 %
Return on Assets xxxxxxxxxxxxxxx-24.48 %
Return on Equity xxxxxxxxxxxxxxx-26.21 %
Return on Total Capital xxxxxxxxxxxxxxx-30.66 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-34.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx182 M
Price To Book Value xxxxxxxxxxxxxxx2.26

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.9 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx48 M
Research & Development xxxxxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

18/11/2024

1

Speculative Buy

$0.70

122.22%

Bell Potter highlights a strong update from the Phase I Insight-003 trial, evaluating Eftilagimod alpha (Efti) in combination with Keytruda and chemotherapy for first-line non-small cell lung cancer (1L NSCLC) patients.

The trial reported a median overall survival of 32.9 months for the first 21 patients, surpassing the 22 months observed in the historical Keytruda and chemotherapy Phase III trial (Keynote-189), explain the analysts.

Bell Potter maintains a Speculative Buy rating and a target price of $0.70.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.30 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.60 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

13/09/2024

1

Overweight

$1.05

233.33%

Wilsons considers ivonescimab's efficacy as "impressive" versus Keytruda.

The analyst believes there are several reasons why it's not as relevant to the upcoming trials of TACTI-004 for Immutep.

No change to Overweight rating and $1.05 target price.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.50 cents.
Access Extra Coverage Research History >

IMM STOCK CHART

FNArena News on IMM

1
Australian Broker Call *Extra* Edition – Jan 29, 2025

Jan 29 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Dec 16, 2024

Dec 16 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Nov 19, 2024

Nov 19 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Sep 18, 2024

Sep 18 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 13, 2024

Sep 13 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps